AbbVie's migraine drug Qulipta gets new FDA nod

Chicago, USA-based drugmaker AbbVie (NYSE: ABBV) has announced that the US Food and Drug Administration (FDA) has approved expanding the indication of Qulipta (atogepant) for the preventive treatment of migraine in adults.

The approval makes Qulipta the first and only oral calcitonin gene-related peptide (CGRP) receptor antagonist approved to prevent episodic and chronic migraine.

"The only company with three treatments across the spectrum of migraine"Roopal Thakkar, senior vice president, chief medical officer, AbbVie, said: “Since September 2021, Qulipta has helped people living with episodic migraine prevent migraine attacks, reducing the daily burden of migraine. Now, those with the most challenging-to-treat chronic migraine can also rely on Qulipta to significantly reduce their migraine days.